TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort

AbstractEarly-onset breast cancer may be due to Li –Fraumeni Syndrome (LFS). Current national and international guidelines recommend thatTP53 genetic testing should be considered for women with breast cancer diagnosed before the age of 31  years. However, large studies investigatingTP53 mutation prevalence in this population are scarce. We collected nationwide laboratory records for all young breast cancer patients tested forTP53 mutations in the Netherlands. Between 2005 and 2016, 370 women diagnosed with breast cancer younger than 30  years of age were tested forTP53 germline mutations, and eight (2.2%) were found to carry a (likely) pathogenicTP53 sequence variant. AmongBRCA1/BRCA2 mutation negative women without a family history suggestive of LFS or a personal history of multiple LFS-related tumours, theTP53 mutation frequency was
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 11 October 2019Source: Biosensors and BioelectronicsAuthor(s): Weiqing Xu, Lei Jiao, Huarong Ye, Zhenzhong Guo, Yu Wu, Hongye Yan, Wenling Gu, Dan Du, Yuehe Lin, Chengzhou ZhuAbstractEstrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) are the three crucial biomarkers for the clinical diagnosis of breast cancer. Sensitive and precise detection of ER, PR, and HER2 is of great significance for the diagnosis of breast cancer. Herein, through a simple solvent-induced self-assembly process, the self-carried allochroic nanoparticles were prepar...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
ConclusionThese results indicate that G-875A is a protective factor against BC, especially from luminal-A subtype, but may promote anaplasia in established tumors, consistent with TGF β signaling roles in BC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsTaselisib in combination with a taxane has a challenging safety profile. Despite evidence of antitumor activity, the benefit –risk profile was deemed not advantageous. Further development is not planned.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsThe present study demonstrates that, in plasma-derived exosomes, high  baseline CDK4 mRNA levels are associated with response to palbociclib plus hormonal therapy, while the increase in TK1 and CDK9 mRNA copies/ml is associated with clinical resistance.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
We present a pathological perspective of our experience. PMID: 31598347 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Authors: Bae SJ, Ahn SG, Yoon CI, Yang BS, Lee HW, Son EJ, Jeong J Abstract Purpose: We evaluated the clinical value of breast magnetic resonance imaging (MRI) in patients who underwent breast-conserving surgery (BCS). The degree of correlation between pathology size and MRI or ultrasonography (US) size was compared based on breast cancer subtypes. In addition, we investigated the positive margin rates. Methods: Patients with invasive breast cancer who underwent preoperative breast MRI and US between 2011 and 2016 were included in the study. Lin's concordance correlation coefficient was used to measure the corr...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Conclusion: Changes in biomarker status are not rare, and usually occur in an unfavorable direction in breast cancer metastases. Negative conversion of ER status is a predictor of poor prognosis. Thus, it is beneficial to evaluate changes in biomarker status in MBC not only for the purpose of determining treatment options but also for prognostication of patients. PMID: 31598343 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Conclusion: Despite the low pCR rate, the tumor response and BCS conversion rates after NAC of luminal HER2- breast cancer were similar to those of other subtypes. NAC has the potential benefit of reducing the size of breast cancer, thereby increasing the BCS conversion rate in luminal HER2- breast cancer. PMID: 31598341 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
How have the recently updated ASCO/CAP HER2 FISH testing guidelines for breast cancer impacted positivity rates?American Journal of Clinical Pathology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Laboratory Medicine | Netherlands Health | Study | Women